In the wave of precision medicine, an emerging field targeting the human body's "second genome" - gut microbiota is bursting with amazing energy.Recently, Shanghai TreatGut Biology Technology Co., Ltd. (hereinafter referred to as "TreatGut Biology"), a leading company in China's microecological medical field, announced the successful completion of strategic investment delivery. The lead investor in this round is Suzhou Jinhe Phase III Equity Investment Partnership (Limited Partnership) (Jinhe Capital), an investment institution deeply involved in the medical and health industry.

Modern lifestyle, abuse of antibiotics and other factors have led to a surge in the number of people with intestinal microecological imbalance worldwide. A large number of studies have shown that gut microbiota disorders are closely related to digestive system diseases (such as Clostridium difficile infection, inflammatory bowel disease), metabolic diseases (such as obesity, diabetes), neurological diseases (such as autism, depression) and even tumor immunotherapy response. However, it is often difficult for traditional drugs to accurately regulate complex bacterial flora networks, and revolutionary intervention methods are urgently needed.

The core competitiveness of TreatGut Biology is exactly what it buildsThe world’s first Precision Microbiota Transplantation Therapy Platform (Precision Microbiota Transplantation Therapy, PMTT)All-in-one platform. This is not a simple "fecal bacterial transplant", but a complete solution based on in-depth bacterial community analysis, precise matching, standardized preparation, precise transplantation and intelligent delivery:

● “Fine screening” sample library:Establish a strictly screened, high-quality healthy donor library and a huge bacterial sample database.

● “Intelligent distribution” technology platform:Advanced technologies such as metagenomics and metabolomics are used to deeply analyze the characteristics of patients' flora and intelligently match the most suitable healthy donor flora.

● “Intelligent manufacturing” standardized products:Relying on the advanced GMP standard preparation center, we realize the standardized, large-scale and traceable production of various dosage forms such as bacterial solutions and capsules to ensure safety and effectiveness. Its core product "liquid live bacteria enteric-coated capsules" has demonstrated significant clinical value.

● “Closed-loop” ecosystem:Integrate the entire chain of "screening-preparation-preparation-delivery-administration-adjusting" to form a complete closed loop from diagnosis to treatment.

TreatGut Biology flora library

Six core technology platforms

Like a "navigator" and "repair agent" that introduces precise regulation into the disordered microecological world, TreatGut Biology's technology platform is becoming a potential key to solving a variety of difficult-to-treat diseases.Up to now, its solutions have been used in clinical applications and research cooperation in many top hospitals, serving more than 300,000 patients in total, and have shown encouraging results in a variety of indications.

As an investor in this round, Jinhe Capital has deep industry insights and rich investment experience in the medical and health field. It is optimistic about and invests in TreatGut Biology. The core logic is:

● Huge blue ocean market:The global microecological medical market has huge potential, especially in the fields of chronic diseases, immune regulation and other fields where the demand is urgent and has not yet been met. As a country with a large population, China has particularly broad market prospects.

● Solid technical barriers:TreatGut Biology has established significant technical barriers and first-mover advantages in terms of accurate bacterial colony matching, standardized preparation, and clinical transformation, with a deep moat.

● Clear business path:The company's pipeline layout is clear, its core products have proven effective in some indications, and it is actively exploring new indications, with a clear commercialization path.

● Top team strength:The founding team has top scientific research background, rich industrial experience and excellent execution capabilities, which is the key to leading the development of the industry.

The project leader of Jinhe Capital said: "Microecological intervention is one of the important development directions of future medicine. As a pioneer and leader in this field in China, TreatGut Biology's innovative PMT technology platform and full industry chain layout have disruptive potential. We are optimistic about the company's ability to solve major clinical needs and look forward to its promotion of the industrialization process of microecological medicine and benefiting a wider patient group."

Next, we will analyze how they work together to achieve double improvements in surgical safety and efficiency.

The completion of this round of comprehensive financing of over 100 million yuan has injected strong development momentum into TreatGut Biology. Funds will mainly be used for:

● Deepen core platform technologies:Continue to optimize the precise matching algorithm and improve the preparation process and automation level.

● Accelerate clinical research and registration:Promote large-scale, multi-center clinical trials of core products on key indications, and accelerate the registration and application process at home and abroad.

● Expand indication layout:Explore the application potential of PMT in broader fields such as tumor immunotherapy enhancement and neuropsychiatric diseases.

● Improve commercial network:Strengthen market education and channel construction to promote the implementation of precise microecological treatment plans.

● Strengthen the construction of bacterial library and database:Further expand the scale of high-quality donor libraries and bacterial population data and consolidate the foundation for research and development.

The "hidden world" composed of trillions of microorganisms in the human intestine contains new hope for disease treatment. Shanghai TreatGut Biology, with its innovative "Precision Microbiota Transplantation" technology, seems to hold the key to this treasure house.Jinhe Capital’s strategic investment is not only an affirmation of its past achievements, but also a strong endorsement of its vision to reshape the future billion-dollar micro-ecological medical landscape.

As precision medicine reaches deeper into the microcosm of gut microbiota, TreatGut Biology is leading a silent but potentially far-reaching medical revolution. We hope that this precisely controlled "microecological engine" can bring a new hope of cure to more patients suffering from diseases.